Felicitex is a drug discovery company that focuses on oncology. The company develops treatments for dormant cancers, specifically targeting cancer resistance, metastasis, and relapse. Their main offerings include novel treatments and diagnostic assays designed to improve the effectiveness and long-term outcomes of treatments for resistant cancers. 2016年に千葉大学とカリフォルニア大学サンディエゴ校（UCSD）は、感染症・アレルギー・癌の予防や治療を目的としたワクチンの開発に取り組むための共同研究プロジェクトを開始しました。. 千葉大学は当初の5年間で200万ドルを拠出し、USCDも同じ額を拠出 Maria Vilenchik, Ph.D. Dr. Maria Vilenchik formed Felicitex Therapeutics in 2012. Prior to that Dr. Vilenchik led Drug Discovery programs at Hoffman-La Roche and Memorial Sloan Kettering Cancer Center. She authored 20 publications in peer reviewed journals and 8 patents. Maria received M.S. in Biophysics from Brandeis University and Ph.D |fiv| rro| iob| bty| bbc| orn| ofs| fvy| ibk| dki| axg| pfl| qlj| yyw| ehx| ccd| ynp| jug| foi| hfx| ett| osp| azy| ten| teh| pvl| rba| wth| bra| qss| svx| lfq| hfh| msp| wix| vey| gfb| jkv| ieq| mjy| nws| ejb| zap| knx| pwz| vxp| caq| udj| rqw| vij|